Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Squamous Cell Carcinoma of the Head and Neck
Ipilimumab for Head and Neck Cancer Patients
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune…
- Trial name
- NCT02812524
- Testing
- Intratumoral Ipilimumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Providence Health & Services
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Head and Neck Cancer
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
RATIONALE: Gathering information about allergies to metals may help doctors learn whether having an allergy to metal used in dental work increases the risk of developing oral cancer.
- Trial name
- NCT00693550
- Testing
- metal patch tests
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Circulating Tumor Cell, HNSCC
Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly.
- Trial name
- NCT06755762
- Testing
- Organoid 3D culture
- Where
- Taiwan
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Squamous Cell Carcinoma of the Head and Neck
Nutrition and Life QUality Patients With Head and Neck Cancers
Malnutrition is currently a major factor of morbidity and mortality, which poses a major public health problem in developing countries but also, albeit to a lesser degree and for different reasons, for industrialized countries.
- Trial name
- NUQUE2 (NCT02510859)
- Testing
- Systematic nutritional consultation at home
- Where
- France
- Volunteers
- 117 people
- Sponsor
- University Hospital, Caen
Head and Neck Cancer
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01194635
- Testing
- fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction
- Volunteers
- 69 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
An open-label, non-randomized, phase II study to assess the safety and efficacy of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Cell Carcinoma patients
- Trial name
- NCT04548440
- Testing
- Sintilimab, Nab paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Locally Advanced Head and Neck Squamous Cell Carcinoma
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
This study is a single-arm exploratory study conducted in LAHNSCC. Eligible patients received two cycles of pembrolizumab immunotherapy in combination with albumin-bound paclitaxel and cisplatin induction chemotherapy, followed…
- Trial name
- NCT06572514
- Testing
- immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Head and Neck Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00675233
- Testing
- HPPH, laser therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Roswell Park Cancer Institute
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
This phase I trial is studying the side effects and best dose of gefitinib when given together with radiation therapy with or without cisplatin in treating patients with stage III or stage IV head and neck cancer.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00033449
- Testing
- gefitinib, radiation therapy, cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
This phase I trial studies the side effects and best dose of pazopanib hydrochloride (pazopanib) when given together with cetuximab in treating patients with incurable recurrent or metastatic head and neck cancer.
- Trial name
- HNSCC (NCT01716416)
- Testing
- Pazopanib, Cetuximab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Squamous Cell Carcinoma, Oropharynx Cancer
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
This proposal explores the novel hypothesis that the variability in outcomes within the Intermediate Risk(IR) HPV-positive Oropharynx Squamous Cell Carcinoma(OPSCC) cohort can be exploited to identify a subpopulation that…
- Trial name
- NCT03342378
- Testing
- Intensity modulated radiotherapy (IMRT), PET-MRI
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Cancer of the Head and Neck
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
The purpose of this study is to determine whether the addition of the fully human EGFr antibody zalutumumab to primary curative radiotherapy increases locoregional control in Squamous Cell Carcinomas of the Head and Neck.
- Trial name
- NCT00496652
- Testing
- Radiotherapy, Zalutumumab
- Where
- Denmark
- Volunteers
- 619 people
- Sponsor
- Danish Head and Neck Cancer Group
Squamous Cell Carcinoma of the Head and Neck
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To characterize the safety of Imprime PGG +…
- Trial name
- NCT03246685
- Testing
- Imprime PGG, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HiberCell, Inc.
Head and Neck Squamous Cell Carcinoma, Quality of Life
Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients
Health-related Quality of Life (QoL) is a multidimensional construct that allows us to know the patient's perception of well-being, and how this perception is related to their illness and treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Quality of Life, Radiotherapy; Complications
- Trial name
- NCT03720158
- Testing
- Omega 3 Group
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Esophageal Squamous Cell Carcinoma
Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy.
- Trial name
- NCT01973725
- Testing
- Icotinib Hydrochloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yuhong Li
Head and Neck Neoplasms, Head and Neck Cancer
Heavy Strength Training in Head and Neck Cancer Survivors
Despite improvements in treatments, head and neck cancer survivors (HNCS) still endure acute and chronic side effects such as loss of muscular strength, limitations in physical functioning, fatigue, and swallowing difficulties…
- Conditions
- Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma
- Trial name
- LIFTING2 (NCT06289049)
- Testing
- Experimental
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- University of Alberta
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.